Detalhe da pesquisa
1.
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
Br J Haematol
; 201(6): 1097-1102, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36921595
2.
A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells.
Cytotherapy
; 16(11): 1537-1544, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25287602
3.
Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance.
Clin Cancer Res
; 28(8): 1712-1723, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191474
4.
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
Leukemia
; 36(3): 760-771, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34584203
5.
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies.
Oncoimmunology
; 8(1): e1512458, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30546950
6.
Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer.
Oncotarget
; 9(2): 1760-1771, 2018 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29416729
7.
Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Immunotherapy
; 5(10): 1039-42, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24088074
8.
Results of a Phase II clinical trial with Id-protein-loaded dendritic cell vaccine in multiple myeloma: encouraging or discouraging?
Immunotherapy
; 4(10): 991-4, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23148751